Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb;21(2):305-7.
doi: 10.3201/eid2102.141649.

Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses

Andrea Marzi, Friederike Feldmann, Thomas W Geisbert, Heinz Feldmann, David Safronetz

Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses

Andrea Marzi et al. Emerg Infect Dis. 2015 Feb.

Abstract

We demonstrated that previous vaccination with a vesicular stomatitis virus (VSV)-based Lassa virus vaccine does not alter protective efficacy of subsequent vaccination with a VSV-based Ebola virus vaccine. These findings demonstrate the utility of VSV-based vaccines against divergent viral pathogens, even when preexisting immunity to the vaccine vector is present.

PubMed Disclaimer

Figures

Figure
Figure
Effect of sequential vaccination with recombinant vesicular stomatitis virus (VSV)–based vaccines on protective efficacy afforded by each vaccine in nonhuman primates. Vaccination with a VSV-based Lassa virus vaccine encoding the Lassa virus glycoproteins provides complete and possibly sterile immunity against a lethal Lassa virus (LASV) challenge. Approximately 90 days after receiving the initial VSV–Lassa vaccine, animals were vaccinated with a VSV-based Ebola virus (EBOV) vaccine. Although we observed a robust VSV-specific immune response, the VSV–Ebola virus vaccine provided complete and possibly sterile immunity against a lethal Zaire Ebola virus challenge. EHF, Ebola hemorrhagic fever.
See this image and copyright information in PMC

References

    1. Falzarano D, Feldmann H. Vaccines for viral hemorrhagic fevers-progress and shortcomings. Curr Opin Virol. 2013;3:343–51. - PMC - PubMed
    1. DeBuysscher BL, Scott D, Marzi A, Prescott J, Feldmann H. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. Vaccine. 2014;32:2637–44. 10.1016/j.vaccine.2014.02.087 - DOI - PMC - PubMed
    1. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11:786–90. 10.1038/nm1258 - DOI - PubMed
    1. Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, Liebscher R, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2005;2:e183. 10.1371/journal.pmed.0020183 - DOI - PMC - PubMed
    1. Brown KS, Safronetz D, Marzi A, Ebihara H, Feldmann H. Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus. J Virol. 2011;85:12781–91. 10.1128/JVI.00794-11 - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources